DBV Technologies S.A.: DBV Technologies to Participate in Upcoming EAACI 2022 Congress

Montrouge, France, June 28, 2022 DBV Technologies to Participate in Upcoming EAACI 2022 Congress DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), a clinical-stage

Related Keywords

Germany ,Montrouge ,France General ,France ,Czech Republic ,United States ,Prague ,Praha ,Hlavníesto ,United Kingdom ,American ,Luciana Tanno ,Susanne Lau ,Antonella Muraro ,Anne Pollak ,Angela Marcucci ,Pharis Mohideen ,Mayte Suarez Farinas ,Exchange Commission ,Company Adss ,A Potent Technology To Address Food Allergies ,European Academy Of Allergy ,Stock Market ,European Academy ,Clinical Immunology ,Annual Scientific ,Basophil Activation Test ,Chief Medical Officer ,Viaskin Peanut ,Professor Gideon Lack ,Professor Antonella ,Collective Effort ,Better Qualify ,Potent Technology ,Address Food Allergies ,Peanut Allergy ,Burden Caused ,Children Between ,Oral Abstract ,Novel Approach ,Predicting Peanut Challenge Outcomes Using ,Serum Parameters ,Machine Learning ,Exhibit Hall ,North American ,Basking Ridge ,Euronext Paris ,Nasdaq Global Select Market ,Des March ,Technologies ,Articipate ,Pcoming ,Caaci ,022 ,Congress ,